Harbin Medisan Pharmaceutical Co., Ltd.

002900

CNE1000032V9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 17/07/2024 am IST			5-day change	1st Jan Change
8.49 ^CNY	-1.16%		+0.12%	-37.80%

29/05	Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Dividend of A Shares for 2023, Payable on 05 June 2024	CI
26/04	Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	CI

Tranche Update on Harbin Medisan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 31, 2019.

January 10, 2020

From January 1, 2020 to January 8, 2020, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 6,815,183 shares, representing 2.15% for CNY 87.17 million under the buyback announced on January 31, 2019.

Latest news about Harbin Medisan Pharmaceutical Co., Ltd.

Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Dividend of A Shares for 2023, Payable on 05 June 2024	30/05	CI
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	27/04	CI
Medisan Pharma's Potassium Chloride Injection Passes Drug Regulator's Evaluation	26/04	MT
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/23/26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/23/24	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022, Payable on May 31, 2023	18/23/18	CI
Harbin Medisan Pharma Gets Patent Rights of China Pharmaceutical University-Developed Drug	04/23/04	MT
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022	27/23/27	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Management Appointments	29/22/29	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	26/22/26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	25/22/25	CI
Harbin Medisan Pharmaceutical Co., Ltd. Implements Final Cash Dividend for 2021, Payable on June 13, 2022	08/22/08	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend Proposal for 2021	19/22/19	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Cash Dividend Proposal for 2021	28/22/28	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/22/26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	26/21/26	CI
Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	29/21/29	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2020, Payable on July 5, 2021	30/21/30	CI
Harbin Medisan Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2020	20/21/20	CI
Harbin Medisan Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020	29/21/29	CI
Harbin Medisan Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	27/21/27	CI
Harbin Fuerjia Technology Development Co., Ltd. completed the acquisition of Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd..	01/21/01	CI
Harbin Fuerjia Technology Development Co., Ltd. agreed to acquire Harbin Beixing Pharmaceutical Co., Ltd from Harbin Medisan Pharmaceutical Co., Ltd. for CNY 570 million.	10/21/10	CI

Chart Harbin Medisan Pharmaceutical Co., Ltd.

Duration

Period

Chart Harbin Medisan Pharmaceutical Co., Ltd.

More charts

Company Profile

HARBIN MEDISAN PHARMACEUTICAL CO LTD is a China-based company principally engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients (APIs), medical devices and cosmetics. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The Company's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The Company mainly distributes its products within domestic market.

Sector

Pharmaceuticals

Calendar

30/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARBIN MEDISAN PHARMACEUTICAL CO., LTD.	-37.80%	362M
ELI LILLY AND COMPANY	+55.35%	815B
NOVO NORDISK A/S	+32.46%	597B
JOHNSON & JOHNSON	-0.10%	377B
MERCK & CO., INC.	+15.47%	319B
ABBVIE INC.	+13.10%	310B
ASTRAZENECA PLC	+16.57%	247B
NOVARTIS AG	+14.88%	228B
AMGEN INC.	+16.54%	180B
PFIZER, INC.	+4.31%	170B